Different Approaches to Maternal Hypotension During Cesarean Section

NCT00991627 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2010-08-27

No results posted yet for this study

Summary

The aim of this study is to compare two different therapeutic approaches to blood pressure reduction: pharmacological vs. non-pharmacological. The setting is that of patients undergoing scheduled Cesarean section under spinal anesthesia and suffering from aorta-caval compression syndrome, which causes a sudden drop in blood pressure.

Conditions

  • Pregnancy
  • Cesarean Section
  • Anesthesia,Spinal
  • Hypotension

Interventions

DRUG

Bupivacaine

10 mg of a 5 mg/ml hyperbaric solution, intrathecally

DRUG

Morphine

200 µg of a 100 µg/ml solution, intrathecally

DRUG

Lactated Ringer's solution

25 ml/min intravenously

DRUG

Ephedrine, continuous infusion

37.5 mg/h intravenously

DRUG

Ephedrine, bolus

6.25 mg IV bolus prn. Hypotension defined according to study protocol for each arm.

DRUG

Atropine

0.1 mg/kg iv bolus prn Bradycardia defined as 50% drop in heart rate from baseline values.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria di Parma

    collaborator OTHER
  • University of Parma

    lead OTHER

Principal Investigators

  • Guido Fanelli, MD · Dept. of Anesthesiology and Critical Care Medicine, University of Parma, Italy

  • Andrea Cornini, MD · UO II Anestesia, Rianimazione e Terapia Antalgica, Azienda Ospedaliero-Universitaria di Parma

  • Michele Zasa, MD · Dept. of Anesthesiology and Critical Care Medicine, University of Parma, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00991627 on ClinicalTrials.gov